Licenses Of Seven Labs Revoked For Violations As Gujarat Cracks Down On Private Drug Testing Labs

Mumbai: In a decisive move to enforce stringent regulatory standards, the Gujarat Food and Drug Control Administration (FDCA) has revoked the licenses of seven private drug testing laboratories. This action followed a series of risk-based inspections targeting 19 labs across Ahmedabad, Baroda, and parts of South Gujarat.

The inspections, which aimed to ensure compliance with critical norms related to impurities, reference standards validation, calibration, testing tools, and instrumentation, revealed significant violations. Dr. H G Koshia, commissioner of the Gujarat FDCA, detailed the findings and the subsequent actions taken.

“We have 54 drug testing labs in Gujarat, out of which 19 were inspected. Serious violations were detected, following which stop testing orders and show cause notices were issued. Seven labs were put under strict scrutiny, and they were directed to resume their operations only after achieving full compliance,” stated Dr. Koshia.

He further explained that the crackdown underscores the FDCA’s commitment to maintaining high standards in drug testing processes, which are crucial for ensuring the safety and efficacy of pharmaceuticals. The revocation of licenses serves as a stern warning to other labs to adhere strictly to regulatory requirements.

This initiative is part of a broader strategy to enhance the reliability and integrity of drug testing procedures in the state, ultimately aiming to safeguard public health. The FDCA has reiterated its zero-tolerance policy towards non-compliance and vowed to continue rigorous inspections across all remaining laboratories.

The affected labs are now required to implement corrective measures and demonstrate adherence to prescribed norms before they can resume operations. This move is expected to prompt all drug testing facilities in Gujarat to reinforce their compliance frameworks and ensure adherence to the highest standards of practices.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert